Transdermal Drug Delivery: Clinical Considerations for the Obstetrician–Gynecologist

@article{Potts2005TransdermalDD,
  title={Transdermal Drug Delivery: Clinical Considerations for the Obstetrician–Gynecologist},
  author={R. Potts and R. Lobo},
  journal={Obstetrics \& Gynecology},
  year={2005},
  volume={105},
  pages={953-961}
}
INTRODUCTION: The first transdermal drug delivery system was introduced in the United States over 20 years ago. Created as an alternative route of administration to improve patient compliance as well as to reduce side effects, the transdermal delivery of drugs now represents a $1.5 to $2 billion market and is growing rapidly. DATA SOURCES: The medical literature from 1980 to 2005 was searched using the PubMed search engine. The search term was “transdermal,” limited to human clinical trials… Expand
Transdermal hormonal contraception: benefits and risks.
  • R. Burkman
  • Medicine
  • American journal of obstetrics and gynecology
  • 2007
TLDR
Clinical data demonstrated the efficacy and safety of the contraceptive patch; however, concerns regarding estrogen levels and reports of venous thromboembolism led to the development of 2 epidemiologic studies and, subsequently, revised product labeling. Expand
TRANSDERMAL DRUG DELIVERY: A TECHNICAL WRITEUP
TLDR
An overview of skin permeation pathways, types of tra nsdermal drug delivery system, methods of preparation with different methods of evaluation, and the recent advancement in transdermalDrug delivery, which includes Transfersomes, Magnetophoresis, Controlled Heat Aided Drug Delivery System, Laser Radiation, Medicated Tattoos, Laser radiation is provided. Expand
Transdermal contraception methods: today’s patches and new options on the horizon
  • A. Nelson
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2015
TLDR
Two new contraceptive patches with lower estrogen levels have been developed and extensively tested and the results of their clinical trials are described, including information about efficacy, bleeding patterns and tolerability. Expand
A REVIEW ON TRANSDERMAL PATCHES
Transdermal drug delivery systems (TDDS) permit delivery of contained drug into the circulation via permeation through skin layers at a controlled rate. These systems ar simple to use and take awayExpand
Transdermal delivery of combined hormonal contraception: a review of the current literature
TLDR
The transdermal patch provides an alternative to COCs for women who want autonomy and the benefit of not needing to take a pill daily, with similar efficacy and tolerability. Expand
Patches: A Novel approach for development of topical drug delivery system
TLDR
Developing new drug delivery system will improves the therapeutic efficacy and safety of drug by more precise (i.e. site specific), special and temporal placement within the body there by reducing both the size and number of doses. Expand
Transdermal contraceptive patches
TLDR
Clinical studies have demonstrated that these two new patch systems may be attractive alternative forms of contraception, since ovulation inhibition has been achieved in all subjects who wear the transdermal patch for 3 weeks, replacing it on a weekly basis. Expand
Novel dissolving microneedles for enhanced transdermal delivery of levonorgestrel: In vitro and in vivo characterization.
TLDR
A novel dissolving microneedle system with improved dissolving ability for the delivery of poorly water soluble contraception drug, levonorgestrel (LNG), resulted in a similar pharmacokinetic profile as that following oral administration. Expand
Transdermal ethinyl estradiol and norelgestromin for contraception
TLDR
Clinical data are reviewed to support the use of the transdermal contraceptive patch as a method of birth control, and study results are not consistent, and the rates of venous thromboembolism are significantly lower than those experienced by pregnant women. Expand
FORMULATION AND EVALUATION OF TRANSDERMAL PATCHES OF RASAGILINE MESYLATE
The purpose of this research work was to develop and evaluate matrix-type transdermal patches containing RasagilineMesylate with HPMC K4M prepared by the solvent evaporation technique. TheExpand
...
1
2
3
...

References

SHOWING 1-10 OF 42 REFERENCES
Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study.
TLDR
The 20-cm(2) patch (Ortho Evra) provided ovulation suppression, cycle control, and safety similar to that of Ortho-Cyclen, with significantly better compliance. Expand
Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial.
TLDR
The contraceptive patch is comparable to a combination OC in contraceptive efficacy and cycle control and Compliance was better with the weekly contraceptive patch than with the OC. Expand
Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler.
TLDR
It is found that, despite low compliance with the recommended dose of the spray and inhaler and differences in product ratings, overall, there are no notable differences between the products in their effects on withdrawal discomfort, perceived helpfulness, or general efficacy. Expand
The effect of site of application on the transcutaneous absorption of 17‐&bgr; estradiol from a transdermal delivery system (Climara)
TLDR
The buttocks seem to be an acceptable site for the application for this once‐weekly 17‐&bgr; estradiol transdermal delivery system, and this application site may provide an advantage in women who experience menopausal symptoms at the end of the week. Expand
Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk
TLDR
Oral but not transdermal ERT is associated with risk of VTE in postmenopausal women, and data suggest that transder mal ERT might be safer than oral ERT with respect to thrombotic risk. Expand
Transdermal Drug Transport and Metabolism. I. Comparison of In Vitro and In Vivo Results
TLDR
Using excised human skin and tissue grafted to athymic mice, the in vitro and in vivo delivery and metabolism of a salicylate diester were compared and suggest that in vitro results may overestimate metabolism because of increased enzymatic activity and/or decreased capillary removal. Expand
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
TLDR
Lower N-desethyloxybutynin plasma concentration and greater saliva output during transdermal treatment correspond to the reported low incidence of dry mouth in patients with overactive bladder and minimizes metabolism to N- Desethyloxy butynin compared with extended-release oral administration. Expand
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
TLDR
The use of conjugated equine estrogen (CEE) increases the risk of stroke, decreases therisk of hip fracture, and does not affect CHD incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years, indicating no overall benefit. Expand
Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch.
TLDR
A daily 1.0 mg estradiol dose as a transdermal gel seems to correspond with a matrix-type patch releasing 50 microg estradio daily in the extent of estradiola absorption. Expand
Current reversible contraceptive methods: a global perspective
  • C. Huezo
  • Medicine
  • International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • 1998
TLDR
Reversible methods of contraception are described including possible health risks and contraindications, which are essential for people to make an appropriate choice of contraception and to secure safe and effective use of the method. Expand
...
1
2
3
4
5
...